Keyword: Reata Pharmaceuticals
Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.
The positive result tees Reata up to file for FDA approval of the activator of Nrf2 and expand development to other neurodegenerative diseases.
After ponying up more than $800 million on its deal with Reata Pharmaceuticals, AbbVie is calling it quits.
The phase 2 trial linked the Nrf2 activator to improvements in estimated glomerular filtration rate, a measure of kidney damage.
CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.
The results come from a small, exploratory study Reata initiated after wrapping up a trial of the drug in its primary indication.